Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Clinical Remission in Severe T2‐High Asthma in Real Life After Anti‐IgE, Anti‐IL‐5 and Anti‐IL5R: A Potential Role for CRP as a Biomarker
Saved in:
| Published in: | Clinical and Translational Allergy |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: Clinical Remission in Severe T2‐High Asthma in Real Life After Anti‐IgE, Anti‐IL‐5 and Anti‐IL5R: A Potential Role for CRP as a Biomarker
- Feasibility of a 50% Dosing Interval Extension of Anti–IL-5 Biologics in Patients with Severe Asthma in Clinical Remission: A Real-World Validation Study
- Benralizumab Reduces Asthma Exacerbations and Costs Among Medicare Beneficiaries with Severe Asthma: The ZEPHYR-5 Study
- Clinical Remission in Patients with Severe Eosinophilic Asthma – A Single-Arm Observational Study with Benralizumab
- High‐dimensional multiomics reveals perturbations to IL‐6/IL‐6R axis and RUNX3 in CD4+ T cells during third‐trimester pregnancy
- Differences in Type 2 Phenotype and Clinical Characteristics of Adult Asthma Patients with Different Severity, Across GINA Step 1 to 5 Asthma
- Standardizing a Four-Marker Basophil Activation Test: Influence of Storage Time, Temperature, and IgE Levels